Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Eisai Limited
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor Fluctuations
To evaluate the long-term safety and tolerability of E2007 in subjects with Parkinson’s disease (PD) who experience end-of-dose “wearing-off” motor fluctuations
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A Study on the Effect of E5501 (study drug) in Subjects with Chronic Hepatitis C Virus (HCV)-related Thrombocytopenia who are Potential Candidates for Antiviral Treatment
To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Disease (GERD)
To compare efficacy (i.e. healing and symptom relief) of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg after 4-8 weeks of treatment among subjects with erosive GERD (eG...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A study done to determine the concentration of the investigational drug, perampanel (E2007) (called, "Study Drug") in the child's blood over a period of time
The primary objective of the study is to evaluate the PK of perampanel during the Maintenance Period of the Core Study following oral suspension administration given as an adjunctive therapy in pediat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
The study being done to see if the Study Drug is safe, tolerable, and can help control seizure in children with epilepsy who are aged 4 to less than 12 years of age and who are already taking seizure medications. The study will also look at pharmacokinetics, which is used to find out the concentration of perampanel in your child’s blood over a period of time
To evaluate the safety and tolerability of perampanel oral suspension when administered as an adjunctive therapy in children (ages 4 to <12 years) with inadequately controlled partial-onset seizures (...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
Estudio de Fase II multicéntrico, abierto con dos fases para la evaluación preliminar de la eficacia y la seguridad de E 7389 en pacientes con cáncer de próstata avanzado o metastásico refractario a tratamiento hormonal, se realizara una estratificación en relación a la quimioterapia previa A Phase II Multicenter, Open Label, Two-Stage Design Study Evaluating E7389 in Patients with Hormone Refractory Prostate Cancer with Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
El objetivo primario del estudio es evaluar la eficacia de E7389 en el tratamiento de pacientes con cáncer de próstata hormonorefractario avanzado/metastásico con y sin quimioterapia previa con un age...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A clinical trial with a daily dose of E7449, a Poly(ADP-Ribose) Polymerase (PARP) Inhibitor, in patients with Advanced Solid Tumors or with Hematological Tumors and in Combination with Chemotherapy (Temozolomide[TMZ] or with Carboplatin and Paclitaxel) in patients with Advanced Solid Tumors
Primary objective: - Determine maximum tolerated dose (MTD) as single agent, once daily (QD) continuously in 28-day cycles - Determine MTD of E7449, QD for 7 consecutive days in combination with TMZ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients with Painful Diabetic Neuropathy
The primary objective of this study will be to provide evidence of the effectiveness of E2007 for treating the pain of diabetic peripheral neuropathy. (PDN)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
An open label study of Zonegran (zonisamide) in patients with partial onset seizures
To determine the efficacy and safety of adjunctive open label zonisamide treatment in patients with refractory partial seizures
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis
To demonstrate that eritoran tetrasodium treatment of subjects with severe sepsis results in a reduction in 28-day all-cause mortality.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
1
2
3
4
5
Suivant